Chemours director awarded 7,182 company shares
Brokaw George R reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Brokaw George R reported acquisition or exercise transactions in this Form 4 filing.
Director George R. Brokaw of Chemours Co received an award of 7,182 shares of Common Stock on May 6, 2026. The shares were granted at $0.00 per share as compensation rather than a market purchase. Following this grant, his direct holdings, including deferred stock units and dividend equivalent units, total 21,642.7173 shares of Chemours common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 7,182 | $0.00 | $0.00 |
Footnotes (1)
- F1. Includes deferred stock units and dividend equivalent units.
Key Figures
Key Terms
deferred stock units financial
dividend equivalent units financial
Grant, award, or other acquisition financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Chemours (CC) director George R. Brokaw report?
What does the transaction code "A" mean in the Chemours (CC) Form 4 for George R. Brokaw?
Are derivative securities involved in George R. Brokaw’s Chemours (CC) Form 4 filing?
What does the footnote about deferred stock units mean in the Chemours (CC) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.